Insomnia drug helps jet-lag, shift-work troubles

WASHINGTON (Reuters) - An insomnia drug that helps the body produce more of the sleep hormone melatonin may improve sleep for jet-lagged travelers and shift workers, researchers reported on Monday.

Maryland-based Vanda Pharmaceuticals Inc. reported on two studies of its drug tasimelteon, also known as VEC-162, that showed it helped patients sleep longer and more deeply than a placebo.

They said that people with so-called circadian rhythm disorders could be helped. These disorders are common causes of insomnia that affect millions of people whose activities are out of sync with their internal body clocks.

These disorders entail persistent sleep disturbances, insomnia when trying to sleep and excessive sleepiness while trying to remain awake, the researchers said.

“…Tasimelteon has the potential for the treatment of patients with transient insomnia associated with circadian rhythm sleep disorders, including people affected by jet lag, or those who work at night, and early-riser workers,” they wrote in their report, published in the Lancet medical journal.

Dr. Shantha Rajaratnam of Brigham and Women’s Hospital and Harvard Medical School in Boston and colleagues, working with the company, did both Phase II and Phase III trials of the drug, aiming to show it is safe and works.

Volunteers slept in labs and were tested using devices known as polysomnographs, which measure sleep activity.

Patients given tasimelteon fell asleep faster, had better sleep and woke up faster, they reported. The drug did not cause any more side-effects than a placebo, they noted.

Melatonin can fight jet lag too but over-the-counter melatonin products are not regulated, they pointed out, and have not been consistently shown to help treat jet lag and other sleep disorders.

The market is potentially large. The study quoted U.S. labor statistics as finding that about 20 percent of the workforce or about 19.7 million U.S. workers are early risers who start work between 2:30 a.m. and 7 a.m.

“Most of these people probably experience chronic sleep restriction because they are unable to initiate and maintain sleep when they attempt to sleep in the early or late evening hours. Tasimelteon might alleviate this problem by advancing the sleep-wake cycle, by providing a direct sleep-promoting effect, or both,” they wrote.

In a commentary, Dr. Daniel Cardinali of the University of Buenos Aires and Dr Diego Golombek, National University of Quilmes in Argentina, noted that drugs such as valium can be addictive.

“Shift-workers, airline crew, tourists, football teams, and many others will welcome the results of Shantha Rajaratnam and colleagues’ study in The Lancet today,” they wrote.

(Reporting by Maggie Fox; Editing by Cynthia Osterman)


Related Posts:

NEW YORK (Reuters Health) - More than half of people with a rare sleep disorder develop a neurodegenerative disease, such as Parkinson’s disease, within 12 years of being diagnosed, results of a Canadian study published Wednesday indicate. So-called “REM sleep behavior disorder” affects a small percentage of the population, Dr. Ronald B. Postuma, at McGill University

Full Post: Rare sleep disorder may be a harbinger of dementia

By Bill Berkrot and Ransdell Pierson NEW ORLEANS (Reuters) - Sanofi-Aventis’s experimental drug Multaq significantly reduced the incidence of hospitalization and length of hospital stays in patients with atrial fibrillation, according to a new analysis of a previously reported study, researchers said on Tuesday. Multaq, known chemically as dronedarone, cut the total number of hospital days by

Full Post: Sanofi’s Multaq reduces hospitalization: study

By Julie Steenhuysen CHICAGO (Reuters) - The popular antidepressant Lexapro showed promise at easing anxiety symptoms in older adults, but the effect was “modest” and would need to be studied further, U.S. researchers said on Tuesday. They said antidepressants like Lexapro, made by Forest Laboratories Inc and known generically as escitalopram, may be useful as a new

Full Post: Lexapro may ease anxiety in older adults: study

NEW YORK (Reuters Health) - People with Parkinson’s disease who also suffer from depression may find they’re helped more by an older class of antidepressants than newer types of medication, a small clinical trial sponsored by the National Institutes of Health suggests. The study found that paroxetine (brand name, Paxil), a so-called SSRI antidepressant, appears to

Full Post: Older antidepressants work for Parkinson patients

NEW YORK (Reuters Health) - Exercise may improve sleep patterns in people with insomnia or sleep disruptions related to periodic leg movements, according to study findings reported by Brazilian researchers. Dr. Marco Tulio de Mello and colleagues at Federal University of Sao Paulo-UNIFESP assessed the effects of acute intensive exercise on sleep patterns in 22 volunteers

Full Post: Physical exercise may ease nocturnal leg movement

Site Navigation

Most Read